Publications in collaboration with researchers from Institut d'Investigació Biomèdica Girona (11)

2021

  1. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment

    Frontiers in Immunology, Vol. 12

2020

  1. Immune Cell Associations with Cancer Risk

    iScience, Vol. 23, Núm. 7

2019

  1. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  2. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin

    Frontiers in Oncology, Vol. 9, Núm. MAR

2018

  1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

2017

  1. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84

  2. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

  3. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749

2015

  1. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

    Clinica Chimica Acta, Vol. 438, pp. 67-69

  2. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

    Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457